Hims & Hers Shares Slide 2.6% to $15.84; EPS Forecast Plummets 82%
Shares of Hims & Hers Health closed at $15.84, down 2.64%, underperforming the S&P 500’s 0.56% gain and the Medical sector’s 0.65% rise, and have slid 46.6% over the past month. The company is expected to report Q4 EPS of $0.02, down 81.8%, on $619.19 million revenue, up 28.7%.
1. Stock Performance
On February 18, shares closed at $15.84, down 2.64%, trailing the S&P 500’s 0.56% gain, Nasdaq’s 0.78% advance and the Dow’s 0.26% rise. Over the past month, the stock has declined 46.6%, versus a 0.65% increase in the Medical sector and a 1.27% drop in the S&P 500.
2. Earnings Outlook
Hims & Hers is set to release Q4 results on February 23, with EPS expected at $0.02, a drop of 81.8% year-over-year, and revenue forecast at $619.19 million, up 28.7%. Full-year consensus estimates call for EPS of $0.48 (+77.8%) and revenue of $2.35 billion (+59.1%).
3. Valuation and Analyst Rankings
Analyst consensus has reduced the Q4 EPS estimate by 3.09% over the past month, contributing to a rank of 4 (sell). The stock trades at a forward P/E of 29.8, above the industry average of 21.6, and a PEG ratio of 3.04 versus the industry’s 1.28, highlighting a premium valuation.